November 16, 2016 - By Louis Casey · 0 Comments
The stock of Steadymed Limited Ord (NASDAQ:STDY) registered an increase of 545% in short interest. STDY’s total short interest was 12,900 shares in November as published by FINRA. Its up 545% from 2,000 shares, reported previously. With 7,300 shares average volume, it will take short sellers 2 days to cover their STDY’s short positions. The short interest to Steadymed Limited Ord’s float is 0.14%. About 602 shares traded hands. Steadymed Ltd (NASDAQ:STDY) has declined 12.99% since April 14, 2016 and is downtrending. It has underperformed by 17.68% the S&P500.
SteadyMed Ltd. is a specialty pharmaceutical company. The company has a market cap of $74.54 million. The Firm is focused on the development and commercialization of various therapeutic product candidates. It currently has negative earnings. The Company’s primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension .
Out of 3 analysts covering SteadyMed (NASDAQ:STDY), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. SteadyMed has been the topic of 5 analyst reports since August 14, 2015 according to StockzIntelligence Inc. H.C. Wainwright initiated Steadymed Ltd (NASDAQ:STDY) rating on Monday, November 7. H.C. Wainwright has “Buy” rating and $10 price target. The stock of Steadymed Ltd (NASDAQ:STDY) has “Buy” rating given on Sunday, August 16 by RBC Capital Markets. RBC Capital Markets maintained it with “Outperform” rating and $13.0 target price in Friday, November 13 report. RBC Capital Markets maintained the shares of STDY in a report on Friday, August 14 with “Outperform” rating. As per Wednesday, October 7, the company rating was reinitiated by JMP Securities.
SteadyMed Ltd., incorporated on June 15, 2005, is a specialty pharmaceutical company. The Firm is focused on the development and commercialization of various therapeutic product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs. The Company’s primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). The Firm is also developing approximately two products for the treatment of post-surgical and acute pain in the home setting, which include bupivacaine PatchPump for local anesthesia post-surgery and ketorolac PatchPump for short-term management of moderately severe acute pain. The Company’s product candidates are enabled by its PatchPump.
More news for Steadymed Ltd (NASDAQ:STDY) were recently published by: Streetinsider.com, which released: “Form 8-K SteadyMed Ltd. For: Nov 14” on November 14, 2016. Streetinsider.com‘s article titled: “SteadyMed Ltd. (STDY) Completes Trevyent Manufacturing Requirements for NDA …” and published on September 01, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey